Does Medicare Cover Wegovy, Zepbound or Ozempic for Weight Loss in 2026?
Yes for Wegovy and the Zepbound KwikPen, if you qualify: the Medicare GLP-1 Bridge covers them for weight management at $50 a month. Ozempic is not in the Bridge, and basic Part D does not pay for it solely for weight loss.
Check the exact drug, form and reason it is prescribed before you pay.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

On Medicare? Here's the path
Coverage is live: $50/mo for Wegovy, Zepbound & Foundayo
Eligible Part D beneficiaries can access covered GLP-1 drugs for $50/mo through the Medicare GLP-1 Bridge. Your prescriber must submit a prior authorization request. Being under 65 does not automatically rule you out: eligibility starts at age 18 and also depends on plan and clinical criteria. See the CMS eligibility rules.
Read first
Medicare GLP-1 Bridge enrollment guide →
What's covered, who qualifies, how prior auth works.
Then check
Check my Bridge eligibility →
Review the criteria before speaking with your prescriber.
Medicare GLP-1 coverage changes constantly. Get Bridge enrollment alerts by email →
Comparing self-pay options?
If the Bridge does not fit your situation, check whether your medication is covered through your Part D plan. You can also compare self-pay programs below. These programs offer compounded options that are not FDA-approved and should not be assumed equivalent to the branded products. Featured partners may pay us a commission; scores are set by our methodology, never by payment.
from $49/mo · Visit →
7.6/10 · GoodChecked Oct 16, 2026; a rating claim didn't match Trustpilot.from $59/mo + $199/year membership after 21 days · Visit →
7.2/10 · FairChecked Sep 15, 2026; some details not published.from $69/mo, billed yearly · Visit →
7.6/10 · GoodChecked Oct 16, 2026; a rating claim didn't match Trustpilot.In this article
- 01Which Medicare coverage route fits your prescription?
- 02Does Medicare cover Ozempic without diabetes?
- 03Does Medicare cover Wegovy for weight loss or heart disease?
- 04Does Medicare cover Zepbound?
- 05Who can use the $50 Medicare GLP-1 Bridge?
- 06Does the $50 copay count toward Part D spending?
- 07What should you ask before booking a provider?
- 08What happens to Medicare GLP-1 coverage in 2027?
- 09Sources and verification
Medicare can pay for Wegovy for weight management in 2026 through the $50 Medicare GLP-1 Bridge, if you meet its eligibility rules. Ozempic is not included in the Bridge. Medicare lists the covered products and conditions.
The distinction is the prescription’s purpose. Basic Part D excludes drugs used solely for weight loss, while a GLP-1 prescribed for a covered medical indication may follow ordinary Part D rules.
The Bridge operates separately, outside your drug plan’s usual benefit. HHS explains the weight-loss exclusion; CMS explains the separate Bridge.
Write down the exact brand, formulation and reason your clinician is prescribing it. Then use the table below to identify which coverage question to ask. A provider’s “insurance accepted” badge cannot answer all three.
Which Medicare coverage route fits your prescription?
The 2026 Medicare drug list includes Wegovy injection and tablets, Foundayo tablets and Zepbound KwikPen for eligible Bridge patients. Ordinary Part D uses a different set of coverage rules.
Use the table to find which route to ask about. It cannot confirm that your own prescription will be paid. Covered Bridge formulations.
| Prescription and purpose | Route to check | What changes the answer |
|---|---|---|
| Wegovy injection or tablet for weight management | Medicare GLP-1 Bridge | Eligibility, prior Part D use and authorization; $50 per eligible monthly supply. |
| Wegovy injection or tablet for cardiovascular risk reduction | Ordinary Part D | Adult established cardiovascular disease plus overweight or obesity; plan rules apply. |
| Wegovy injection for qualifying MASH liver disease | Ordinary Part D | Adult noncirrhotic MASH with F2-F3 fibrosis; this indication does not apply to tablets. |
| Ozempic for type 2 diabetes or its approved related heart/kidney indications | Ordinary Part D | The specific indication, formulary and authorization requirements. |
| Ozempic solely for weight loss | Not a Bridge product; excluded from basic Part D for this use | Ask your clinician about an appropriate treatment, rather than assuming the Wegovy route transfers. |
| Zepbound for weight management | Bridge, for KwikPen only | Single-dose vials and single-dose pens are excluded. |
| Zepbound for moderate-to-severe obstructive sleep apnea in an adult with obesity | Ordinary Part D | Plan formulary and authorization rules apply; this diagnosis excludes Bridge access. |
| Foundayo tablet for weight management | Medicare GLP-1 Bridge | The same program eligibility review is required. |
Indication boundaries come from the Wegovy label, Ozempic label and FDA's Zepbound sleep-apnea approval. CMS distinguishes Part D treatment indications from Bridge weight management.
A drug being eligible for Part D coverage does not guarantee it is on your plan’s formulary.
Some Part D plans offer supplemental coverage for weight-management drugs beyond the basic benefit. Ask your plan whether that applies to your exact prescription.
A Part D-paid GLP-1 fill in 2026, including supplemental coverage, excludes Bridge access for 2026. CMS explains supplemental coverage and prior use.
See which Medicare route fits you
Answer a few questions to see what to ask your plan and your prescriber. The checker does not confirm eligibility or enrollment.
Check your Medicare coverage route →Does Medicare cover Ozempic without diabetes?
Ozempic has no approved weight-management indication.
Its May 2026 US label lists three uses, all involving type 2 diabetes: blood sugar control, cardiovascular risk reduction with established cardiovascular disease, and kidney-related risk reduction with chronic kidney disease.
Heart or kidney disease alone does not match those labeled uses. Ozempic prescribing information.
For a prescription solely for weight loss, basic Part D’s exclusion still matters. Calling Ozempic “semaglutide,” or seeing that Wegovy is covered, does not make the products interchangeable for insurance.
Ask your prescriber and plan about the documented indication before paying for a consultation intended to obtain a particular drug. HHS Part D coverage explanation.
Does Medicare cover Wegovy for weight loss or heart disease?
Wegovy can have different coverage routes for different uses. Its June 2026 label includes weight management and cardiovascular risk reduction for eligible adults in both injection and tablet form.
Injection also has an indication for certain MASH liver disease; the tablet does not. Wegovy prescribing information, section 1.
The liver indication covers adults with noncirrhotic MASH and moderate to advanced fibrosis, stages F2-F3. That indication received accelerated approval, with confirmatory evidence still required.
A general diagnosis of fatty liver does not by itself establish this labeled indication. Wegovy prescribing information.
When Wegovy is prescribed for an indication coverable under Part D, CMS directs the patient to that pathway. A missing formulary entry does not automatically make the same prescription eligible for the Bridge.
Ask about the plan’s coverage determination or exception process instead. CMS coverage-interaction rules.
For the separate medication-choice question, our Wegovy and Zepbound comparison explains the evidence and formulation differences to discuss with your clinician.
Does Medicare cover Zepbound?
The $50 Medicare GLP-1 Bridge covers Zepbound KwikPen for weight management if you qualify. Its single-dose vials and single-dose pens are excluded from the Bridge.
Separate supplemental plan coverage, where available, follows your plan's rules. Medicare lists the covered Bridge forms; CMS explains supplemental coverage.
If your clinician prescribes Zepbound for moderate-to-severe obstructive sleep apnea and you have obesity, the prescription follows ordinary Part D rules instead, so your plan's formulary and authorization requirements decide it.
That diagnosis also takes the prescription outside the Bridge. FDA's Zepbound sleep-apnea approval; CMS Part D and Bridge rules.
For the Bridge, your prescriber sends the KwikPen prescription to your pharmacy first, then waits for the pharmacy's prior-authorization request. CMS explains the correct sequence.
Our Medicare GLP-1 Bridge guide walks through who qualifies and how the request is processed.
Who can use the $50 Medicare GLP-1 Bridge?
The Bridge requires eligible drug-plan enrollment, age 18 or older, an appropriate weight-management prescription and clinical criteria measured when GLP-1 therapy began.
Its BMI thresholds are more specific than “BMI 30, or BMI 27 with any related condition.” Meeting a BMI threshold alone is not enough.
The thresholds are: CMS clinical criteria.
- •BMI 35 or higher: no additional condition is needed for this clinical threshold.
- •BMI 30 or higher: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher.
- •BMI 27 or higher: prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.
Qualifying enrollment includes a standalone PDP or an eligible Medicare Advantage coordinated-care plan with Part D, including qualifying SNP, EGWP and LI NET enrollment.
Some arrangements, including PACE and private fee-for-service plans, are excluded unless you also hold an eligible standalone PDP where applicable.
Your insurer does not need to opt in, and Humana's role as the processor does not require switching to a Humana plan.
Use our official contact and plan-type guide or CMS's full plan-type list to check uncertain enrollment.
CMS defines uncontrolled hypertension here as systolic pressure above 140 or diastolic pressure above 90 despite two concurrent blood-pressure medicines.
Your prescriber must verify the relevant history and ongoing nutrition and physical-activity plan.
Use our Bridge guide for the detailed access process. CMS provider guidance.
Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced fibrosis excludes Bridge access, even if your plan denies a GLP-1 for that condition.
A Part D-covered GLP-1 fill during 2026 also excludes access in 2026. CMS exclusion and prior-use rules.
Does the $50 copay count toward Part D spending?
No. The Bridge’s $50 monthly drug copay sits outside ordinary Part D: its deductible does not apply, and the payment does not move you toward your Part D out-of-pocket limit.
Keep this amount separate when comparing your prescription budget with your health plan’s statements. CMS copay rules.
Medicare defines a monthly supply as 28 or 30 days, depending on the drug. Extra Help cannot lower this Bridge payment, and the Medicare Prescription Payment Plan cannot spread it across months.
Clinical appointments and other services may bring separate charges, so ask the provider for those costs. Medicare cost details.
Zepbound KwikPen needles are a separate purchase. They are not covered by the Bridge and should not be billed to it or to your Part D plan.
Ask the pharmacy what supplies you will need and their cost. CMS's pen-needle guidance.
Before booking, request separate amounts for the consultation, ongoing visits, laboratory work and any membership. Ask what is billed to Medicare and what you would pay yourself.
A $50 medication copay is not a quote for the entire treatment program.
What should you ask before booking a provider?
Ask about the exact prescription and benefit before choosing a clinic. Medicare’s $50 Bridge drug payment and a provider’s own fees are separate questions, and ordinary Part D coverage may require authorization.
Copy or print this checklist and take it to your clinician, your plan's member services and your pharmacy. Medicare explains the separate costs.
- •Prescription: What exact brand, formulation and treatment indication are we checking?
- •Coverage route: Is this an ordinary Part D claim or a Bridge prescription? Who confirms that route?
- •Part D requirements: Is this formulation covered for my documented indication? What authorization or formulary exception is needed?
- •Bridge requirements: Has the prescriber checked the clinical rules, excluded diagnoses and previous Part D-paid GLP-1 use?
- •Costs: What would I pay for the drug, visits, laboratory work and membership, listed separately?
- •Practical access: Which pharmacy will fill it, and who handles missing paperwork or a rejected claim?
- •Written record: Can I have the coverage decision or reference number and the next action in writing?
For ordinary drug-plan comparisons, start with Medicare Plan Compare. For a possible Bridge prescription, continue to our Medicare GLP-1 Bridge guide.
Keep member numbers and medical records with your care team, pharmacy and insurer; this checklist does not require sending them to us.
What happens to Medicare GLP-1 coverage in 2027?
The Medicare GLP-1 Bridge is scheduled to continue through December 31, 2027. CMS extended it after the planned 2027 Part D launch of BALANCE did not proceed.
Your insurer does not need to opt into the Bridge, so an assumed BALANCE switch is not a reason to change plans. CMS program timeline.
Some details remain unsettled. CMS has not yet specified the prior-GLP-1-use lookback period it will apply in 2027.
Recheck the official rules before relying on a future eligibility decision; do not assume that the 2026 rule automatically carries forward unchanged. CMS prior-use FAQ.
Sources and verification
Coverage rules and US-label references were checked October 23, 2026. The matrix and checklist combine public sources; we did not verify an individual policy or submit a claim.
Your clinician determines treatment suitability and the relevant payer determines coverage.
- Medicare: weight-loss drugs, covered formulations and patient costs
- CMS: Medicare GLP-1 Bridge timeline and copay
- CMS: provider eligibility criteria
- CMS: Part D interactions, exclusions and prior-use rules
- Wegovy US prescribing information, revised June 2026
- Ozempic US prescribing information, revised May 2026
- FDA: Zepbound approval for obstructive sleep apnea
- HHS Office of Inspector General: Part D coverage and weight-loss exclusion
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.




